Tuesday, August 4, 2026

Nikola’s Stock Takes a Nosedive: 17% Drop Shakes Investors

After a recent rally, Nikola's stock dropped over 17% due to profit-taking, closing at $4.38; earlier gains were from hydrogen truck deals.

MIT Study Says AI Doesn’t Hold Values—It Mimics Prompts

MIT's research reveals AI lacks consistent values, responding variably to prompts rather than holding firm opinions.

Samsung’s HBM4 Sales Surpass 1 Billion USD: What This Means for the Future of AI Memory

Samsung Electronics' HBM4 sales exceed $1 billion, driven by AI demand, with projections for significant growth in the coming years.

Tag: FDA

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

HLB Group Appoints Yang Eun-young President of Bio Business Development Division

HLB Group appoints Yang Eun-young as President of Bio Business Development, focusing on global partnerships and commercialization strategies.

Penetrium Bioscience Announces Finalization of New Clinical Strategy for Targeted Cancer Therapies

Penetrium Bioscience reveals new clinical strategy to combat drug resistance in cancer therapies at AACR 2026, launching Phase 2 trials.

CG Bio’s EasyMade TI: The First Custom Titanium Implant Approved by FDA 510(k) – What It Means for Patients

CG Bio's EasyMade TI titanium implant receives FDA 510(k) approval, marking a milestone for customized implants in the U.S. market.

Lunit supplies integrated breast cancer diagnostic solution to Lexington Clinic

Lunit supplies integrated breast cancer AI solutions to Lexington Clinic, enhancing diagnostics and expanding its presence in the Americas.

How ‘Sunlenkaju’ and ‘Sunlenkajeong’ Are Revolutionizing HIV-1 Therapy in 2026

FDA approves lenacapavir-based HIV treatments for patients with multidrug-resistant infections, enhancing options for difficult cases.

Samchundang Pharma CEO Claims FDA Recognition for Obesity Drug as Generic

Samchundang Pharma's CEO announces FDA recognition of oral semaglutide as a generic and withdraws $1.7 billion stock sale plan.

FDA Grants Orphan Drug Status to Tovecimig: What This Means for Cholangiocarcinoma Treatment

ABL Bio's Tovecimig receives Orphan Drug Designation from the FDA, enhancing its approval prospects for cholangiocarcinoma treatment.

CT-P71: The New ADC Cancer Drug Fast-Tracked by FDA for Urothelial Carcinoma

Celltrion's CT-P71 receives FDA Fast Track designation for urothelial carcinoma, enhancing its ADC pipeline and global drug development efforts.

April 2026: Major Regulatory Actions on Herbal Patches and Antibiotics in South Korea

The FDA suspended manufacturing and sales of several products for regulatory violations, including herbal patches and antibiotic tablets.

Exploring Cenobamate: How SK Biopharmaceuticals’ New Oral Suspension Benefits Adult Epilepsy Patients

SK Biopharmaceuticals submits NDA for Cenobamate oral suspension, enhancing treatment options for epilepsy patients with swallowing difficulties.

ABL Bio to Invest Additional $25 Million in Neok Bio to Accelerate ADC Clinical Trials

ABL Bio invests $25M in Neok Bio for bispecific antibody-drug conjugate trials, aiming for FDA-approved treatments by 2027.

Eli Lilly’s New Weight Loss Pill Foundayo: A Game Changer in the GLP-1 Market?

The FDA has approved Eli Lilly's oral obesity drug Foundayo, enhancing competition in the weight loss market with flexible dosing.

Classys Unveils Aggressive Growth Strategy at AAD 2026: What’s Next for the U.S. Market?

Classys reveals its growth strategy for the U.S. market at AAD 2026, showcasing innovative products and emphasizing clinical efficacy.

HLB’s Liraglutide: A Game-Changer in Cholangiocarcinoma Treatment with FDA Priority Review

HLB's Elevar Therapeutics receives FDA Priority Review for lirafugratinib, a promising treatment for cholangiocarcinoma with a 47% response rate.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.